Well-established (Ki67 and p38/ERK) and developing (RNA-seq analysis) dormancy markers should be cross-evaluated across cell lines and diverse dormancy-inducing environments, in both cellular and tumor dormancy regimes, to evaluate how reliably they relate to clinically relevant breast cancer dormancy. This evidence concerns the gene MKI67 and breast cancer.